img

Global Poliomycetes Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Poliomycetes Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Polio vaccines are vaccines used to prevent poliomyelitis. There are two typesone that uses inactivated poliovirus and is given by injection, and one that uses weakened poliovirus and is given by mouth.
The World Health Organization recommends all children be fully vaccinated against polio. The two vaccines have eliminated polio from most of the world, and reduced the number of cases reported each year from an estimated 350,000 in 1988 to 37 in 2022.
The global Poliomycetes Vaccine market size was US$ 709.8 million in 2022 and is forecast to a readjusted size of US$ 835.1 million by 2034 with a CAGR of 2.3% during the forecast period 2024-2034.
Sanofi, GSK and Serum Institute are the top 3 players of Polio Vaccine with about 97% market shares.
In terms of sales (consumption) side, this report focuses on the sales of Poliomycetes Vaccine by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Poliomycetes Vaccine market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Poliomycetes Vaccine market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Sanofi S.A
United Pharma Industries Co Ltd
Gansu Conbest Biotech Co., Ltd.
Shenzhen Mellow Hope Pharm Industrial Co., Ltd.
China National Biotec Group
Serum Institute of India
By Type
Type 1
Type 2
By Application
Hospitals
Clinics
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Poliomycetes Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Poliomycetes Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Poliomycetes Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Poliomycetes Vaccine Definition
1.2 Market by Type
1.2.1 Global Poliomycetes Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Type 1
1.2.3 Type 2
1.3 Market Segment by Application
1.3.1 Global Poliomycetes Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Poliomycetes Vaccine Sales
2.1 Global Poliomycetes Vaccine Revenue Estimates and Forecasts 2018-2034
2.2 Global Poliomycetes Vaccine Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Poliomycetes Vaccine Revenue by Region
2.3.1 Global Poliomycetes Vaccine Revenue by Region (2018-2024)
2.3.2 Global Poliomycetes Vaccine Revenue by Region (2024-2034)
2.4 Global Poliomycetes Vaccine Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Poliomycetes Vaccine Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Poliomycetes Vaccine Sales Quantity by Region
2.6.1 Global Poliomycetes Vaccine Sales Quantity by Region (2018-2024)
2.6.2 Global Poliomycetes Vaccine Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Poliomycetes Vaccine Sales Quantity by Manufacturers
3.1.1 Global Poliomycetes Vaccine Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Poliomycetes Vaccine Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Poliomycetes Vaccine Sales in 2022
3.2 Global Poliomycetes Vaccine Revenue by Manufacturers
3.2.1 Global Poliomycetes Vaccine Revenue by Manufacturers (2018-2024)
3.2.2 Global Poliomycetes Vaccine Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Poliomycetes Vaccine Revenue in 2022
3.3 Global Poliomycetes Vaccine Sales Price by Manufacturers
3.4 Global Key Players of Poliomycetes Vaccine, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Poliomycetes Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Poliomycetes Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Poliomycetes Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Poliomycetes Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Poliomycetes Vaccine Sales Quantity by Type
4.1.1 Global Poliomycetes Vaccine Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Poliomycetes Vaccine Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Poliomycetes Vaccine Sales Quantity Market Share by Type (2018-2034)
4.2 Global Poliomycetes Vaccine Revenue by Type
4.2.1 Global Poliomycetes Vaccine Historical Revenue by Type (2018-2024)
4.2.2 Global Poliomycetes Vaccine Forecasted Revenue by Type (2024-2034)
4.2.3 Global Poliomycetes Vaccine Revenue Market Share by Type (2018-2034)
4.3 Global Poliomycetes Vaccine Price by Type
4.3.1 Global Poliomycetes Vaccine Price by Type (2018-2024)
4.3.2 Global Poliomycetes Vaccine Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Poliomycetes Vaccine Sales Quantity by Application
5.1.1 Global Poliomycetes Vaccine Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Poliomycetes Vaccine Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Poliomycetes Vaccine Sales Quantity Market Share by Application (2018-2034)
5.2 Global Poliomycetes Vaccine Revenue by Application
5.2.1 Global Poliomycetes Vaccine Historical Revenue by Application (2018-2024)
5.2.2 Global Poliomycetes Vaccine Forecasted Revenue by Application (2024-2034)
5.2.3 Global Poliomycetes Vaccine Revenue Market Share by Application (2018-2034)
5.3 Global Poliomycetes Vaccine Price by Application
5.3.1 Global Poliomycetes Vaccine Price by Application (2018-2024)
5.3.2 Global Poliomycetes Vaccine Price Forecast by Application (2024-2034)
6 North America
6.1 North America Poliomycetes Vaccine Sales by Company
6.1.1 North America Poliomycetes Vaccine Revenue by Company (2018-2024)
6.1.2 North America Poliomycetes Vaccine Sales Quantity by Company (2018-2024)
6.2 North America Poliomycetes Vaccine Market Size by Type
6.2.1 North America Poliomycetes Vaccine Sales Quantity by Type (2018-2034)
6.2.2 North America Poliomycetes Vaccine Revenue by Type (2018-2034)
6.3 North America Poliomycetes Vaccine Market Size by Application
6.3.1 North America Poliomycetes Vaccine Sales Quantity by Application (2018-2034)
6.3.2 North America Poliomycetes Vaccine Revenue by Application (2018-2034)
6.4 North America Poliomycetes Vaccine Market Size by Country
6.4.1 North America Poliomycetes Vaccine Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Poliomycetes Vaccine Revenue by Country (2018-2034)
6.4.3 North America Poliomycetes Vaccine Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Poliomycetes Vaccine Sales by Company
7.1.1 Europe Poliomycetes Vaccine Sales Quantity by Company (2018-2024)
7.1.2 Europe Poliomycetes Vaccine Revenue by Company (2018-2024)
7.2 Europe Poliomycetes Vaccine Market Size by Type
7.2.1 Europe Poliomycetes Vaccine Sales Quantity by Type (2018-2034)
7.2.2 Europe Poliomycetes Vaccine Revenue by Type (2018-2034)
7.3 Europe Poliomycetes Vaccine Market Size by Application
7.3.1 Europe Poliomycetes Vaccine Sales Quantity by Application (2018-2034)
7.3.2 Europe Poliomycetes Vaccine Revenue by Application (2018-2034)
7.4 Europe Poliomycetes Vaccine Market Size by Country
7.4.1 Europe Poliomycetes Vaccine Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Poliomycetes Vaccine Revenue by Country (2018-2034)
7.4.3 Europe Poliomycetes Vaccine Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Poliomycetes Vaccine Sales by Company
8.1.1 China Poliomycetes Vaccine Sales Quantity by Company (2018-2024)
8.1.2 China Poliomycetes Vaccine Revenue by Company (2018-2024)
8.2 China Poliomycetes Vaccine Market Size by Type
8.2.1 China Poliomycetes Vaccine Sales Quantity by Type (2018-2034)
8.2.2 China Poliomycetes Vaccine Revenue by Type (2018-2034)
8.3 China Poliomycetes Vaccine Market Size by Application
8.3.1 China Poliomycetes Vaccine Sales Quantity by Application (2018-2034)
8.3.2 China Poliomycetes Vaccine Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Poliomycetes Vaccine Sales by Company
9.1.1 APAC Poliomycetes Vaccine Sales Quantity by Company (2018-2024)
9.1.2 APAC Poliomycetes Vaccine Revenue by Company (2018-2024)
9.2 APAC Poliomycetes Vaccine Market Size by Type
9.2.1 APAC Poliomycetes Vaccine Sales Quantity by Type (2018-2034)
9.2.2 APAC Poliomycetes Vaccine Revenue by Type (2018-2034)
9.3 APAC Poliomycetes Vaccine Market Size by Application
9.3.1 APAC Poliomycetes Vaccine Sales Quantity by Application (2018-2034)
9.3.2 APAC Poliomycetes Vaccine Revenue by Application (2018-2034)
9.4 APAC Poliomycetes Vaccine Market Size by Region
9.4.1 APAC Poliomycetes Vaccine Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Poliomycetes Vaccine Revenue by Region (2018-2034)
9.4.3 APAC Poliomycetes Vaccine Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Poliomycetes Vaccine Sales by Company
10.1.1 Middle East, Africa and Latin America Poliomycetes Vaccine Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Poliomycetes Vaccine Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Poliomycetes Vaccine Market Size by Type
10.2.1 Middle East, Africa and Latin America Poliomycetes Vaccine Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Poliomycetes Vaccine Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Poliomycetes Vaccine Market Size by Application
10.3.1 Middle East, Africa and Latin America Poliomycetes Vaccine Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Poliomycetes Vaccine Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Poliomycetes Vaccine Market Size by Country
10.4.1 Middle East, Africa and Latin America Poliomycetes Vaccine Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Poliomycetes Vaccine Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Poliomycetes Vaccine Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Sanofi S.A
11.1.1 Sanofi S.A Company Information
11.1.2 Sanofi S.A Overview
11.1.3 Sanofi S.A Poliomycetes Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Sanofi S.A Poliomycetes Vaccine Products and Services
11.1.5 Sanofi S.A Poliomycetes Vaccine SWOT Analysis
11.1.6 Sanofi S.A Recent Developments
11.2 United Pharma Industries Co Ltd
11.2.1 United Pharma Industries Co Ltd Company Information
11.2.2 United Pharma Industries Co Ltd Overview
11.2.3 United Pharma Industries Co Ltd Poliomycetes Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 United Pharma Industries Co Ltd Poliomycetes Vaccine Products and Services
11.2.5 United Pharma Industries Co Ltd Poliomycetes Vaccine SWOT Analysis
11.2.6 United Pharma Industries Co Ltd Recent Developments
11.3 Gansu Conbest Biotech Co., Ltd.
11.3.1 Gansu Conbest Biotech Co., Ltd. Company Information
11.3.2 Gansu Conbest Biotech Co., Ltd. Overview
11.3.3 Gansu Conbest Biotech Co., Ltd. Poliomycetes Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Gansu Conbest Biotech Co., Ltd. Poliomycetes Vaccine Products and Services
11.3.5 Gansu Conbest Biotech Co., Ltd. Poliomycetes Vaccine SWOT Analysis
11.3.6 Gansu Conbest Biotech Co., Ltd. Recent Developments
11.4 Shenzhen Mellow Hope Pharm Industrial Co., Ltd.
11.4.1 Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Company Information
11.4.2 Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Overview
11.4.3 Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Poliomycetes Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Poliomycetes Vaccine Products and Services
11.4.5 Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Poliomycetes Vaccine SWOT Analysis
11.4.6 Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Recent Developments
11.5 China National Biotec Group
11.5.1 China National Biotec Group Company Information
11.5.2 China National Biotec Group Overview
11.5.3 China National Biotec Group Poliomycetes Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 China National Biotec Group Poliomycetes Vaccine Products and Services
11.5.5 China National Biotec Group Poliomycetes Vaccine SWOT Analysis
11.5.6 China National Biotec Group Recent Developments
11.6 Serum Institute of India
11.6.1 Serum Institute of India Company Information
11.6.2 Serum Institute of India Overview
11.6.3 Serum Institute of India Poliomycetes Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Serum Institute of India Poliomycetes Vaccine Products and Services
11.6.5 Serum Institute of India Poliomycetes Vaccine SWOT Analysis
11.6.6 Serum Institute of India Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Poliomycetes Vaccine Value Chain Analysis
12.2 Poliomycetes Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Poliomycetes Vaccine Production Mode & Process
12.4 Poliomycetes Vaccine Sales and Marketing
12.4.1 Poliomycetes Vaccine Sales Channels
12.4.2 Poliomycetes Vaccine Distributors
12.5 Poliomycetes Vaccine Customers
13 Market Dynamics
13.1 Poliomycetes Vaccine Industry Trends
13.2 Poliomycetes Vaccine Market Drivers
13.3 Poliomycetes Vaccine Market Challenges
13.4 Poliomycetes Vaccine Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Poliomycetes Vaccine Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Type 1
Table 3. Major Manufacturers of Type 2
Table 4. Global Poliomycetes Vaccine Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Poliomycetes Vaccine Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Poliomycetes Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Poliomycetes Vaccine Revenue Market Share by Region (2018-2024)
Table 8. Global Poliomycetes Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Poliomycetes Vaccine Revenue Market Share by Region (2024-2034)
Table 10. Global Poliomycetes Vaccine Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Doses)
Table 11. Global Poliomycetes Vaccine Sales by Region (2018-2024) & (K Doses)
Table 12. Global Poliomycetes Vaccine Sales Market Share by Region (2018-2024)
Table 13. Global Poliomycetes Vaccine Sales by Region (2024-2034) & (K Doses)
Table 14. Global Poliomycetes Vaccine Sales Market Share by Region (2024-2034)
Table 15. Global Poliomycetes Vaccine Sales Quantity by Manufacturers (2018-2024) & (K Doses)
Table 16. Global Poliomycetes Vaccine Sales Quantity Share by Manufacturers (2018-2024)
Table 17. Global Poliomycetes Vaccine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Poliomycetes Vaccine Revenue Share by Manufacturers (2018-2024)
Table 19. Global Poliomycetes Vaccine Price by Manufacturers 2018-2024 (USD/Dose)
Table 20. Global Key Players of Poliomycetes Vaccine, Industry Ranking, 2021 VS 2022
Table 21. Global Poliomycetes Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Poliomycetes Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Poliomycetes Vaccine as of 2022)
Table 23. Global Key Manufacturers of Poliomycetes Vaccine, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Poliomycetes Vaccine, Product Offered and Application
Table 25. Global Key Manufacturers of Poliomycetes Vaccine, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Poliomycetes Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 28. Global Poliomycetes Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 29. Global Poliomycetes Vaccine Sales Quantity Share by Type (2018-2024)
Table 30. Global Poliomycetes Vaccine Sales Quantity Share by Type (2024-2034)
Table 31. Global Poliomycetes Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Poliomycetes Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Poliomycetes Vaccine Revenue Share by Type (2018-2024)
Table 34. Global Poliomycetes Vaccine Revenue Share by Type (2024-2034)
Table 35. Poliomycetes Vaccine Price by Type (2018-2024) & (USD/Dose)
Table 36. Global Poliomycetes Vaccine Price Forecast by Type (2024-2034) & (USD/Dose)
Table 37. Global Poliomycetes Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 38. Global Poliomycetes Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 39. Global Poliomycetes Vaccine Sales Quantity Share by Application (2018-2024)
Table 40. Global Poliomycetes Vaccine Sales Quantity Share by Application (2024-2034)
Table 41. Global Poliomycetes Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Poliomycetes Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Poliomycetes Vaccine Revenue Share by Application (2018-2024)
Table 44. Global Poliomycetes Vaccine Revenue Share by Application (2024-2034)
Table 45. Poliomycetes Vaccine Price by Application (2018-2024) & (USD/Dose)
Table 46. Global Poliomycetes Vaccine Price Forecast by Application (2024-2034) & (USD/Dose)
Table 47. North America Poliomycetes Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 48. North America Poliomycetes Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 49. North America Poliomycetes Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 50. North America Poliomycetes Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 51. North America Poliomycetes Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 52. North America Poliomycetes Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Poliomycetes Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 54. North America Poliomycetes Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 55. North America Poliomycetes Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 56. North America Poliomycetes Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Poliomycetes Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. North America Poliomycetes Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 59. North America Poliomycetes Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Poliomycetes Vaccine Sales Quantity by Country (2018-2024) & (K Doses)
Table 61. North America Poliomycetes Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 62. Europe Poliomycetes Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 63. Europe Poliomycetes Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 64. Europe Poliomycetes Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 65. Europe Poliomycetes Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 66. Europe Poliomycetes Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Poliomycetes Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Poliomycetes Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 69. Europe Poliomycetes Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 70. Europe Poliomycetes Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Poliomycetes Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Poliomycetes Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 73. Europe Poliomycetes Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Poliomycetes Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Poliomycetes Vaccine Sales Quantity by Country (2018-2024) & (K Doses)
Table 76. Europe Poliomycetes Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 77. China Poliomycetes Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 78. China Poliomycetes Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 79. China Poliomycetes Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 80. China Poliomycetes Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 81. China Poliomycetes Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 82. China Poliomycetes Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Poliomycetes Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 84. China Poliomycetes Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 85. China Poliomycetes Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 86. China Poliomycetes Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Poliomycetes Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 88. APAC Poliomycetes Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 89. APAC Poliomycetes Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 90. APAC Poliomycetes Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 91. APAC Poliomycetes Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 92. APAC Poliomycetes Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Poliomycetes Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 94. APAC Poliomycetes Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 95. APAC Poliomycetes Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 96. APAC Poliomycetes Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Poliomycetes Vaccine Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 98. APAC Poliomycetes Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 99. APAC Poliomycetes Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Poliomycetes Vaccine Sales Quantity by Region (2018-2024) & (K Doses)
Table 101. APAC Poliomycetes Vaccine Sales Quantity by Region (2024-2034) & (K Doses)
Table 102. Middle East, Africa and Latin America Poliomycetes Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 103. Middle East, Africa and Latin America Poliomycetes Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Poliomycetes Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 105. Middle East, Africa and Latin America Poliomycetes Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 106. Middle East, Africa and Latin America Poliomycetes Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Poliomycetes Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Poliomycetes Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 109. Middle East, Africa and Latin America Poliomycetes Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 110. Middle East, Africa and Latin America Poliomycetes Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Poliomycetes Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Poliomycetes Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Poliomycetes Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Poliomycetes Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Poliomycetes Vaccine Sales Quantity by Country (2018-2024) & (K Doses)
Table 116. Middle East, Africa and Latin America Poliomycetes Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 117. Sanofi S.A Company Information
Table 118. Sanofi S.A Description and Overview
Table 119. Sanofi S.A Poliomycetes Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 120. Sanofi S.A Poliomycetes Vaccine Product and Services
Table 121. Sanofi S.A Poliomycetes Vaccine SWOT Analysis
Table 122. Sanofi S.A Recent Developments
Table 123. United Pharma Industries Co Ltd Company Information
Table 124. United Pharma Industries Co Ltd Description and Overview
Table 125. United Pharma Industries Co Ltd Poliomycetes Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 126. United Pharma Industries Co Ltd Poliomycetes Vaccine Product and Services
Table 127. United Pharma Industries Co Ltd Poliomycetes Vaccine SWOT Analysis
Table 128. United Pharma Industries Co Ltd Recent Developments
Table 129. Gansu Conbest Biotech Co., Ltd. Company Information
Table 130. Gansu Conbest Biotech Co., Ltd. Description and Overview
Table 131. Gansu Conbest Biotech Co., Ltd. Poliomycetes Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 132. Gansu Conbest Biotech Co., Ltd. Poliomycetes Vaccine Product and Services
Table 133. Gansu Conbest Biotech Co., Ltd. Poliomycetes Vaccine SWOT Analysis
Table 134. Gansu Conbest Biotech Co., Ltd. Recent Developments
Table 135. Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Company Information
Table 136. Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Description and Overview
Table 137. Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Poliomycetes Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 138. Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Poliomycetes Vaccine Product and Services
Table 139. Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Poliomycetes Vaccine SWOT Analysis
Table 140. Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Recent Developments
Table 141. China National Biotec Group Company Information
Table 142. China National Biotec Group Description and Overview
Table 143. China National Biotec Group Poliomycetes Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 144. China National Biotec Group Poliomycetes Vaccine Product and Services
Table 145. China National Biotec Group Poliomycetes Vaccine SWOT Analysis
Table 146. China National Biotec Group Recent Developments
Table 147. Serum Institute of India Company Information
Table 148. Serum Institute of India Description and Overview
Table 149. Serum Institute of India Poliomycetes Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 150. Serum Institute of India Poliomycetes Vaccine Product and Services
Table 151. Serum Institute of India Poliomycetes Vaccine SWOT Analysis
Table 152. Serum Institute of India Recent Developments
Table 153. Key Raw Materials Lists
Table 154. Raw Materials Key Suppliers Lists
Table 155. Poliomycetes Vaccine Distributors List
Table 156. Poliomycetes Vaccine Customers List
Table 157. Poliomycetes Vaccine Market Trends
Table 158. Poliomycetes Vaccine Market Drivers
Table 159. Poliomycetes Vaccine Market Challenges
Table 160. Poliomycetes Vaccine Market Restraints
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. Poliomycetes Vaccine Product Picture
Figure 2. Global Poliomycetes Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Poliomycetes Vaccine Market Share by Type in 2022 & 2034
Figure 4. Type 1 Product Picture
Figure 5. Type 2 Product Picture
Figure 6. Global Poliomycetes Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Poliomycetes Vaccine Market Share by Application in 2022 & 2034
Figure 8. Hospitals
Figure 9. Clinics
Figure 10. Others
Figure 11. Poliomycetes Vaccine Report Years Considered
Figure 12. Global Poliomycetes Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 13. Global Poliomycetes Vaccine Revenue 2018-2034 (US$ Million)
Figure 14. Global Poliomycetes Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 15. Global Poliomycetes Vaccine Sales Quantity 2018-2034 (K Doses)
Figure 16. Global Poliomycetes Vaccine Sales Quantity Market Share by Region (2018-2024)
Figure 17. Global Poliomycetes Vaccine Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Poliomycetes Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 19. North America Poliomycetes Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Poliomycetes Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 21. Europe Poliomycetes Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Poliomycetes Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 23. China Poliomycetes Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Poliomycetes Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 25. APAC Poliomycetes Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Poliomycetes Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 27. Middle East, Africa and Latin America Poliomycetes Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Poliomycetes Vaccine Sales Quantity in 2022
Figure 29. The Top 10 and Top 5 Players Market Share by Poliomycetes Vaccine Revenue in 2022
Figure 30. Poliomycetes Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Poliomycetes Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 32. Global Poliomycetes Vaccine Revenue Market Share by Type (2018-2034)
Figure 33. Global Poliomycetes Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 34. Global Poliomycetes Vaccine Revenue Market Share by Application (2018-2034)
Figure 35. North America Poliomycetes Vaccine Revenue Market Share by Company in 2022
Figure 36. North America Poliomycetes Vaccine Sales Quantity Market Share by Company in 2022
Figure 37. North America Poliomycetes Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 38. North America Poliomycetes Vaccine Revenue Market Share by Type (2018-2034)
Figure 39. North America Poliomycetes Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 40. North America Poliomycetes Vaccine Revenue Market Share by Application (2018-2034)
Figure 41. North America Poliomycetes Vaccine Revenue Share by Country (2018-2034)
Figure 42. North America Poliomycetes Vaccine Sales Quantity Share by Country (2018-2034)
Figure 43. U.S. Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Poliomycetes Vaccine Sales Quantity Market Share by Company in 2022
Figure 46. Europe Poliomycetes Vaccine Revenue Market Share by Company in 2022
Figure 47. Europe Poliomycetes Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 48. Europe Poliomycetes Vaccine Revenue Market Share by Type (2018-2034)
Figure 49. Europe Poliomycetes Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 50. Europe Poliomycetes Vaccine Revenue Market Share by Application (2018-2034)
Figure 51. Europe Poliomycetes Vaccine Revenue Share by Country (2018-2034)
Figure 52. Europe Poliomycetes Vaccine Sales Quantity Share by Country (2018-2034)
Figure 53. Germany Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 54. France Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 55. U.K. Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 56. Italy Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 57. Russia Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 58. China Poliomycetes Vaccine Sales Quantity Market Share by Company in 2022
Figure 59. China Poliomycetes Vaccine Revenue Market Share by Company in 2022
Figure 60. China Poliomycetes Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 61. China Poliomycetes Vaccine Revenue Market Share by Type (2018-2034)
Figure 62. China Poliomycetes Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 63. China Poliomycetes Vaccine Revenue Market Share by Application (2018-2034)
Figure 64. APAC Poliomycetes Vaccine Sales Quantity Market Share by Company in 2022
Figure 65. APAC Poliomycetes Vaccine Revenue Market Share by Company in 2022
Figure 66. APAC Poliomycetes Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 67. APAC Poliomycetes Vaccine Revenue Market Share by Type (2018-2034)
Figure 68. APAC Poliomycetes Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 69. APAC Poliomycetes Vaccine Revenue Market Share by Application (2018-2034)
Figure 70. APAC Poliomycetes Vaccine Revenue Share by Region (2018-2034)
Figure 71. APAC Poliomycetes Vaccine Sales Quantity Share by Region (2018-2034)
Figure 72. Japan Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 73. South Korea Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 74. China Taiwan Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 76. India Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 77. Middle East, Africa and Latin America Poliomycetes Vaccine Sales Quantity Market Share by Company in 2022
Figure 78. Middle East, Africa and Latin America Poliomycetes Vaccine Revenue Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Poliomycetes Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Poliomycetes Vaccine Revenue Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Poliomycetes Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Poliomycetes Vaccine Revenue Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Poliomycetes Vaccine Sales Quantity Share by Country (2018-2034)
Figure 84. Middle East, Africa and Latin America Poliomycetes Vaccine Revenue Share by Country (2018-2034)
Figure 85. Brazil Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 86. Mexico Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 87. Turkey Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 88. Israel Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 89. GCC Countries Poliomycetes Vaccine Revenue (2018-2034) & (US$ Million)
Figure 90. Poliomycetes Vaccine Value Chain
Figure 91. Poliomycetes Vaccine Production Process
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed